Prognyx oncology intelligence
Live ClinicalTrials.gov oncology trial comparison around an asset, plus landscapes and CI briefings.
Sollte ich dies verwenden
Qualität und Sicherheit
Basierend auf einer automatisierten Analyse der Tool-Definitionen und der Einhaltung des Protokolls.
Kontextkosten
Dies ist die ungefähre Anzahl der Tokens, die jedes Mal verbraucht werden, wenn die Tools des Servers in den Kontext eines Modells geladen werden. Höhere Werte verringern die Aufmerksamkeit, die für andere Aufgaben verfügbar ist.
Installieren
Installation mit einem Klick
Fügen Sie dies Ihrer Datei `claude_desktop_config.json` hinzu:
{
"mcpServers": {
"oncology-intelligence": {
"url": "https://www.prognyx.com/api/mcp"
}
}
}Remote-Endpunkte
https://www.prognyx.com/api/mcpstreamable-httpWas es kann
Tool-Inventar
Tools (3)
🟢compare_trials(asset, indication)
Up to three interventional ClinicalTrials.gov studies matching an asset or target AND an oncology indication, side by side: sponsor, phase, status, declared arms, primary outcomes, last update, registry URL. Active studies first, then later phase; different sponsors where possible. Use a target (e.g. "KIF18A", "B7-H3") rather than one drug name to see other programmes.
Eingabe-Schema
{
"type": "object",
"properties": {
"asset": {
"type": "string",
"maxLength": 80,
"description": "Public asset or target, e.g. \"sotorasib\", \"KRAS G12C\", \"B7-H3\"."
},
"indication": {
"type": "string",
"maxLength": 80,
"description": "Oncology indication, e.g. \"colorectal cancer\", \"NSCLC\"."
}
},
"required": [
"asset",
"indication"
],
"additionalProperties": false
}🟢search_registry(query, limit)
Live landscape for a target, asset, company, indication or NCT number: total and active study counts, leading sponsors, phase mix, the most recently updated studies with URLs, and related Prognyx briefings. Counts for phases and sponsors come from a recent sample, stated in the result.
Eingabe-Schema
{
"type": "object",
"properties": {
"query": {
"type": "string",
"maxLength": 160,
"description": "e.g. \"KRAS G12C\", \"Nuvalent\", \"claudin 18.2 gastric cancer\", \"NCT05132075\"."
},
"limit": {
"type": "integer",
"minimum": 1,
"maximum": 25,
"default": 10,
"description": "Studies to return."
}
},
"required": [
"query"
],
"additionalProperties": false
}🟢search_briefings(query, limit)
Prognyx oncology competitive-intelligence briefings (each claim linked to a primary source) matching a drug, company, target or indication, newest first, with URL, date and summary.
Eingabe-Schema
{
"type": "object",
"properties": {
"query": {
"type": "string",
"maxLength": 120,
"description": "Drug, company, target or indication. Empty returns the latest."
},
"limit": {
"type": "integer",
"minimum": 1,
"maximum": 20,
"default": 5,
"description": "Briefings to return."
}
},
"additionalProperties": false
}Community
Nachweis